The UK Real World Evidence Solutions Market was valued at $281.5 Million in 2025 and projected to reach to $577.8 Million by 2030, representing a compound annual growth rate of 15.5%. The UK Real World Evidence Solutions Market is poised for sustained growth through 2030, driven by NHS modernisation initiatives and increasing recognition of real-world data's value in healthcare delivery.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK Real World Evidence Solutions Market is valued at £281.5 million in 2025 and is projected to reach £577.8 million by 2030, representing a robust 15.5% CAGR over the forecast period.
Growing investment in digital health infrastructure across the National Health Service is accelerating the adoption of real-world evidence solutions, enabling better patient outcomes and operational efficiency.
UK regulatory bodies increasingly support evidence-based healthcare practices, driving adoption of real-world data in clinical decision-making and pharmaceutical development processes.
The UK market CAGR of 15.5% exceeds the global average of 14.8%, positioning the UK as a high-growth market for real-world evidence solutions in Europe.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INTEGRATED DATA SETS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 14.8% from 2025 to 2030 |
| Largest Segment | CLOUD-BASED (Deployment Mode) |
| Market Size Base Year (Billions) | ~USD 5.43 (2025) |
| Revenue Forecast (Billions) | ~USD 10.83 (2030) |
| Segments Covered | Component, Type, Application, Therapeutic Area, Revenue Model, Deployment Mode, End User, Healthcare Payer, Healthcare Provider |
9 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HEALTHCARE PAYERS | 41.5 | 47.5 | 54.3 | 62.2 | 71.3 | 81.8 | 94 | 108.1 | 14.8 |
| HEALTHCARE PROVIDERS | 56.9 | 65.6 | 75.7 | 87.4 | 101.1 | 117.1 | 135.8 | 157.7 | 15.8 |
| MEDTECH COMPANIES | 27.9 | 32.3 | 37.4 | 43.4 | 50.4 | 58.6 | 68.2 | 79.5 | 16.3 |
| OTHER END USERS | 13.7 | 15.7 | 17.9 | 20.4 | 23.3 | 26.7 | 30.6 | 35 | 14.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 72.8 | 83.7 | 96.3 | 110.9 | 127.9 | 147.6 | 170.7 | 197.5 | 15.5 |
| TOTAL | 212.9 | 244.7 | 281.5 | 324.3 | 374 | 431.9 | 499.3 | 577.8 | 15.5 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| IQVIA | United States | Public Company | Technology & Analytics Solutions,Research & Development Solutions,Contract Sales & Medical Solutions, |
| ICON PLC | Ireland | Public Company | Full-service clinical development (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory, bioanalytical, biomarker, and imaging services, |
| SYNEOS HEALTH | United States | Private Company | Clinical Development Services,Commercialization & Launch Services,Consulting, Advisory & Data/Software, |
| PAREXEL INTERNATIONAL (MA) CORPORATION | United States | Private Company | Clinical trial management and monitoring,Biostatistics and data management,Regulatory affairs and pharmacovigilance, |
| FLATIRON HEALTH | United States | Subsidiary | Oncology EHR and practice management software,Life sciences real-world data subscriptions and licensing,Evidence-generation partnerships and analytics services, |
| FORTREA | United States | Public Company | Clinical Development (Phase I–IV and RWE),Clinical Pharmacology and Early Development,Consulting, Market Access, HEOR and RWE Services, |
| ORACLE | United States | Public Company | Cloud SaaS (Fusion ERP/EPM/SCM/HCM, NetSuite, CX),Cloud Infrastructure & Autonomous Database,On-Premise Licenses & License Support, |
| ELEVANCE HEALTH | United States | Public Company | Health Benefits (Commercial & Specialty),Health Benefits (Government: Medicare, Medicaid, FEP),CarelonRx (Pharmacy Services), |
| TRINITY | United States | Public Company | Railcar Leasing and Services Group,Rail Products Group, |
| MEDIDATA | United States | Private Company | Core EDC and clinical data management,Decentralized trial and patient engagement solutions,Advanced analytics and data-driven services, |
IQVIA is a large public company headquartered in the United States with approximately 93,000 employees. The company operates in the healthcare and life sciences industry.
Icon PLC is a public company founded in 1989 and headquartered in Ireland. With 40,350 employees, the company provides clinical research and development services globally.
Syneos Health is a private company founded in 2010 and based in the United States. With 28,768 employees, the company offers clinical research, consulting, and commercial services to the life sciences industry.
Parexel International (MA) Corporation is a private company founded in 1982 and headquartered in the United States. With 18,900 employees, the company provides clinical research, consulting, and regulatory services to the pharmaceutical and biotech industries.
FlatIron Health is a subsidiary company founded in 2012 and based in the United States. The company specializes in oncology software and data solutions for healthcare providers.
Fortrea is a public company founded in 2023 and based in the United States. With 14,000 employees, the company operates in the clinical research and contract research organization sectors.
Oracle is a large public technology company founded in 1977 and headquartered in the United States. With 141,000 employees, the company develops database software, cloud computing solutions, and enterprise applications.
Elevance Health is a public company founded in 2001 and based in the United States. With 96,615 employees, the company operates as a major health insurance and managed care provider.
Trinity is a public company founded in 1933 and headquartered in the United States. With 6,110 employees, the company operates in the healthcare services sector.
Medidata is a private company founded in 1999 and based in the United States. With 1,998 employees, the company provides cloud-based clinical trial software and data analytics solutions for the life sciences industry.
The UK Real World Evidence Solutions Market is valued at £281.5 million in 2025 and is expected to grow to £577.8 million by 2030.
The UK market is growing at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030.
Key drivers include NHS digital transformation initiatives, regulatory support for real-world data in drug approvals, increased adoption of electronic health records, and growing collaboration between healthcare providers and pharmaceutical companies in the UK.
The UK's 15.5% CAGR outpaces the global average of 14.8%, reflecting the country's advanced healthcare infrastructure and strong regulatory framework for real-world evidence adoption.
The NHS is a major driver of RWE adoption in the UK, leveraging real-world data to improve patient outcomes, support clinical decision-making, and enhance post-market surveillance across the healthcare system.
The study involved five activities to estimate the current size of the real world evidence solutions market. Exhaustive secondary research was conducted to collect information on the market and its varied subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of the real world evidence solutions market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends, to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various supply-side & demand-side sources were interviewed to obtain qualitative & quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, biostatisticians, and related key executives from various companies and organizations operating in the real world evidence solutions market. Primary sources from the demand side included industry experts, such as directors of pharmaceutical, biopharmaceuticals, medical device companies, contract manufacturing organizations, directors of RWE vendor companies, directors of clinical research organizations, and other related key executives.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers of companies are defined based on their total revenues. As of 2024. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the RWE solutions market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The market was split into several segments and subsegments after arriving at the overall market size using the market size estimation processes. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the RWE solutions market.
Real world evidence is the clinical evidence about the usage & potential benefits or risks of a medical product derived from real world data analysis. This evidence is derived from the analysis of real world data (RWD), information collected from sources such as electronic health records, insurance claims, patient registries, and data gathered from other sources (such as digital health technologies) that can inform individuals on health status.
Full forecast, segment splits, and company analysis for all Real World Evidence Solutions Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report